Part 1 Lecture 1: enantiomers - implications and complications in developmental pharmacology, M. Eichelbaum. Part 2 Symposium 1 - neuroregulators and neonatal pharmacology: introduction, H. Lagercrantz; expression and release of neuroregulators during development - monoamines and neuropeptides, H. Lagercrantz et al; ischemic damage in the neonatal brain - excitatory amino acids, H. Hagberg; nervous and immune systems as targets for developmental effects of benzodiazepines, M. Schlumpf et al; a review of recent studies. Part 3 Symposium 2 - molecular biology in studies of drug metabolism during development: introduction, T. Cresteil; cytochrome P450-dependent metabolism of dextromethorphan - foetal and adult studies, E. Jacqz-Aigrain and T. Cresteil. Part 4 Symposium 3 - recent advances in growth hormone research: introduction, R. Reppaport et al; treatment of growth failure in renal disease wih recombinant human growth hormone - 2 years' experience, B. Tonshoff and O. Mehls. Part 5 Symposium 4 - early and late behavioural effects of opioids after prenatal exposure: intoduction, W. Lichtensteiger; studies on developmental neurology in the human foetus, G.H.A. Visser et al. Part 6 Symposium 5 - developmental aspects of the mono-aminergic system: thrombocyte monoamine oxidase activity and behaviour deviances in adolescence, M. Cederblad et al; developmental aspects of the monoamine-degrading enzyme monamine oxidase, M. Strolin Benedetti et al; functional changes implicating dopaminergic systems following perinatal treatments, T. Archer and A. Fredriksson; priming as a model of behavioural sensitization, G. Di Chiara et al. Part 7 Lecture 2 - training programme overview: biological markers of intrauterine exposure to cocaine and cigarette smoking, G. Koren et al.
